Osteogenesis imperfecta type I (COL1A1 deficiency) OMIM 166200

In Osteogenesis imperfecta type I (COL1A1, OMIM 166200), the master switch sits on the ↓ DOWN branch ([F] forced below); the healthy state is the ON well. The forced corrective direction is to raise s toward ON branch (polarity: clear). Classification: ✓ Recovers an existing standard. Direction only — no dose, no efficacy magnitude.

The disease maps to an R19 double-well whose corrective lever is read straight off the cusp (barrier 0.5425, γ 1.4731, spinodal 0.6882). The corrective direction is forced [F]; the agent names below are direction-concordant labels at grade [O] (no dose, no efficacy or safety magnitude). This is a research hypothesis offered to experts, not medical advice.

The emergence switch

The switch for Osteogenesis imperfecta type I is an R19 double-well emerged from the real proximal-promoter DNA of COL1A1. Its geometry is fixed by measured stiffness γ (never fitted); the numbers below are read directly off that cusp.

emergent axis
↓ DOWN [F]
healthy branch
ON
lesion
LOF_null
γ (stiffness)
1.4731
barrier
0.5425
spinodal
0.6882
s_on / s_off
1.2137 / -1.2137
fragility
0.26
corrective polarity
clear
forced direction
raise s toward ON branch

Chemistry feasibility (DIRECTION only [O]). small-molecule recrossing of the fold is geometrically harder (barrier 0.5425 at neutral drive; lower barrier = smaller drive to supply). [O] -- no affinity/potency/dose/efficacy asserted.

The derived corrective lever

The cusp forces a corrective direction: raise s toward ON branch. This is the load-bearing output of the framework — it is [F] forced, and it is falsifiable. 2 lever families are derived; the lead is h-restore (drive modulator).

h-restore (drive modulator)sign: decreasegeometric rank 0.26
Mechanism. remove / oppose the drive (clear the accumulating load that pins the disease branch)
Applies to. allele-agnostic (downstream/environmental tilt)
favoured when the switch is fragile -- a small drive shift recrosses the fold
Falsifier. If clearing/opposing the accumulating FDPS does NOT relieve the disease branch in a COL1A1 model, the h-restore(clear) lever is refuted for this axis.
gamma-restore (stabiliser / chaperone)sign: Nonegeometric rank 0.00
Mechanism. N/A
Applies to. none (honest exclusion)
EXCLUDED: null allele -- no product to stiffen
Falsifier. If a folding-stabiliser/chaperone does NOT re-deepen the healthy well for a residual COL1A1 allele (no rescue that a null allele lacks), the gamma-restore lever is refuted; null alleles are excluded by construction.

Agents mapped onto the lever

✓ Agreement with established practice. The corrective direction derived here (raise s toward ON branch) independently matches an agent already in clinical use for this disease: bisphosphonate (pamidronate / zoledronate). The geometry recovered known medicine — this is a validation signal for the logic, not a new treatment claim by this kit.
Existing agents whose known action is direction-concordant with the derived lever (status as pinned in the corpus; no dose, no efficacy magnitude).
agent (class)dir.statusphasemap
bisphosphonate (pamidronate / zoledronate)
Glorieux 1998 NEJM 339:947 (pamidronate, severe OI)
decreaseapproved4✓ in use
anti-sclerostin antibody (romosozumab -- investigational in OI)
Glorieux 2017 (anti-sclerostin, OI trials)
decreaseclinical3◇ in trials
⚠ Mechanism-direction only — do not self-administer; no dose (unvalidated; set by a physician / national authority); not an approved use.

Direction-only candidate leads (corpus join)

Each lead is surfaced only because its known mechanism points the same way as the derived lever, and each comes with a source and a falsifier. None is a treatment.

pamidronate✓ recovered standarddir: decrease · approved
Class. aminobisphosphonate (osteoclast anti-resorptive)
Mechanism. An aminobisphosphonate that suppresses osteoclast-mediated bone resorption, lowering the abnormally high bone turnover and the fragility that the type-I collagen deficit produces, and raising bone mass. Direction on the disease axis: decrease / oppose the resorption-driven fragility drive. Engaged node: COL1A1. Allele scope: agnostic -- acts on the bone-remodelling phenotype irrespective of the COL1A1 variant. Gene-specific to COL1A1 (unique among the 113). Phenotype-modifying: it does not correct the collagen-I lesion, exactly as the corpus's celiprolol entry modifies the vascular phenotype of COL3A1 disease rather than the collagen-III lesion. Established standard of pharmacologic care for osteogenesis imperfecta; the decrease direction recovers that established standard.
✓ This is a rediscovery. Cyclic aminobisphosphonate (pamidronate; zoledronic acid interchangeable) is the established standard of pharmacologic care for osteogenesis imperfecta; suppressing osteoclastic resorption lowers the high-turnover fragility drive, which is the disease-axis decrease direction, recovering the established standard. Phenotype-modifying, not a correction of the COL1A1 lesion -- the same established-standard basis the corpus uses for celiprolol in vascular Ehlers-Danlos.
Safety (qualitative; no magnitude). first-infusion acute-phase reaction and transient hypocalcaemia signals (qualitative; no magnitude); osteonecrosis-of-jaw and atypical-femur concerns with prolonged use; paediatric administration at specialist centres; zoledronic acid is an interchangeable aminobisphosphonate
Falsifier. If pamidronate (a gene-specific decrease agent) clearing/opposing the accumulating load does NOT relieve the DOWN [F] disease branch in a COL1A1 model, the h-restore(clear) direction is refuted for pamidronate here.
Source: Glorieux 1998 NEJM 339:947 (cyclic intravenous pamidronate in severe osteogenesis imperfecta)
⚠ Mechanism-direction only — do not self-administer; no dose (unvalidated; set by a physician / national authority); not an approved use.

Evidence & provenance

What is reproduced vs. cited for this page.
elementgradebasis
R19 switch & cusp geometry (this page)[V] verifiedemerged from measured promoter γ of COL1A1; deterministic, 2×sha256 identical
corrective direction[F] forcedforced by the cusp sign; falsifiable (see lever falsifiers)
mapped agents / leads[O] opendirection-concordance only; corpus-pinned (2026-06-21); no dose, no efficacy/safety magnitude

Reading the agent column. VALIDATION SIGNAL -- the agent is already approved / established standard for this disease, so the direction logic recovered known clinical practice. Not a new claim by this kit. GENUINE HYPOTHESIS -- no approved indication for this disease; the direction match is a direction-only, untested [O] lead. Basis field grades the evidence (investigational here / in a related condition / off-label / speculative).